Table 2.
Percentage of hMBP-, (84–98)MBP-peptide and (143–168)MBP-peptide reactive TCLs in MS paptients and controls
| MBP | (84–98)MBP-peptide | (143–168)MBP-peptide | |||||
|---|---|---|---|---|---|---|---|
| HLA-DR | No· positive | % positive | No· positive | % positive | No· positive | % positive | |
| Patients | |||||||
| MS1 | 17 | 17/200 | 8·5 | 3/11 | 27·3 | 5/11 | 45·4 |
| MS2 | 7/16 | 11/250 | 4·4 | 1/7 | 14·2 | 0/7 | 0·0 |
| MS3 | 14/17 | 27/250 | 10·8 | 1/16 | 6·2 | 4/16 | 35·0 |
| MS4 | 103/13 | 6/250 | 2·4 | 2/5 | 40·0 | 1/5 | 20·0 |
| MS5 | 1/7 | 1/250 | 0·4 | 0/1 | 0·0 | 1/1 | 100·0 |
| MS6 | 7/16 | 10/218 | 44·6 | 4/7 | 57·1 | 2/7 | 28·6 |
| MS7 | 15/16 | 6/200 | 3·0 | 1/3 | 33·3 | 2/3 | 66·6 |
| MS8 | 15/17 | 8/80 | 6·2 | 0/4 | 0·0 | 1/4 | 25·0 |
| MS9 | 103/15 | 5/250 | 2·0 | 2/5 | 40·0 | 4/5 | 80·0 |
| Total | – | 91/1946 | 4·7* | 14/58 | 24·1† | 20/58 | 34·5‡ |
| Controls | |||||||
| C1 | 7/16 | 10/250 | 4·0 | 2//8 | 33·0 | 1/8 | 12·5 |
| C2 | 4/9 | 31//250 | 12·4 | 3/28 | 10·7 | 1/28 | 3·5 |
| C3 | 11 | 15/250 | 6·0 | 3/12 | 25·5 | 0/12 | 0·0 |
| C4 | 10/17 | 7/250 | 2·8 | 1/6 | 16·6 | 2/6 | 33·3 |
| C5 | 7/17 | 18/250 | 7·0 | 3/6 | 50·0 | 1/6 | 16·6 |
| C6 | 15/16 | 19/63 | 30·0 | 1/7 | 14·2 | 1/7 | 14·2 |
| C7 | 9/15 | 11/280 | 3·9 | 2/8 | 25·0 | 2/8 | 25·0 |
| C8 | 15/18 | 17/218 | 7·8 | 1/14 | 7·1 | 3/14 | 21·4 |
| Total | – | 128/1811 | 7·0 | 16/89 | 18·0 | 11/89 | 12·3 |
*
NS versus MBP control
†
NS versus (84–98) control
‡
P < 0·05 versus (143–168) control; P < 0·05 versus (84–98) MS